These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11444200)

  • 1. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
    Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
    Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
    Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
    Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
    Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
    Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
    Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
    Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
    Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
    Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.
    Diebold J; Seemüller F; Löhrs U
    Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotype and K-RAS mutation in mucinous ovarian adenocarcinoma with mural nodule of high-grade sarcoma: case report.
    Desouki MM; Fadare O; Kanbour A; Kanbour-Shakir A
    Int J Gynecol Pathol; 2014 Mar; 33(2):186-90. PubMed ID: 24487474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
    Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
    Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection.
    Takeshima Y; Amatya VJ; Daimaru Y; Nakayori F; Nakano T; Inai K
    Hum Pathol; 2001 Nov; 32(11):1203-8. PubMed ID: 11727259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
    Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
    Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
    Werness BA; DiCioccio RA; Piver MS
    Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
    Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
    Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
    Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
    Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations.
    Cuatrecasas M; Matias-Guiu X; Prat J
    Am J Surg Pathol; 1996 Jun; 20(6):739-46. PubMed ID: 8651354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and clinical correlations of ras gene mutations in human ovarian tumors.
    Varras MN; Sourvinos G; Diakomanolis E; Koumantakis E; Flouris GA; Lekka-Katsouli J; Michalas S; Spandidos DA
    Oncology; 1999; 56(2):89-96. PubMed ID: 9949292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.